Lindbrook Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $13.2K | Buy |
1,757
+154
| +10% | +$1.16K | ﹤0.01% | 1537 |
|
|
2024
Q4 | $12.1K | Sell |
1,603
-468
| -23% | -$3.52K | ﹤0.01% | 1553 |
|
|
2024
Q3 | $15.7K | Sell |
2,071
-747
| -27% | -$5.68K | ﹤0.01% | 1423 |
|
|
2024
Q2 | $17.4K | Buy |
2,818
+2,278
| +422% | +$14.1K | ﹤0.01% | 1324 |
|
|
2024
Q1 | $2.74K | Sell |
540
-144
| -21% | -$731 | ﹤0.01% | 2134 |
|
|
2023
Q4 | $4.1K | Buy |
684
+353
| +107% | +$2.11K | ﹤0.01% | 1989 |
|
|
2023
Q3 | $2.34K | Sell |
331
-686
| -67% | -$4.86K | ﹤0.01% | 2067 |
|
|
2023
Q2 | $7.16K | Buy |
1,017
+752
| +284% | +$5.29K | ﹤0.01% | 1641 |
|
|
2023
Q1 | $2.21K | Buy |
265
+49
| +23% | +$409 | ﹤0.01% | 2203 |
|
|
2022
Q4 | $2.48K | Buy |
216
+76
| +54% | +$873 | ﹤0.01% | 2145 |
|
|
2022
Q3 | $2K | Sell |
140
-78
| -36% | -$1.11K | ﹤0.01% | 1994 |
|
|
2022
Q2 | $2K | Sell |
218
-8
| -4% | -$73 | ﹤0.01% | 1912 |
|
|
2022
Q1 | $4K | Buy |
+226
| New | +$4K | ﹤0.01% | 1672 |
|
|
2020
Q2 | – | Sell |
-248
| Closed | – | – | 1727 |
|
|
2020
Q1 | $0 | Buy |
+248
| New | – | ﹤0.01% | 1689 |
|